Melanoma Clinical Trial
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining bryostatin 1 with interleukin-2 may kill more tumor cells.
PURPOSE: Randomized phase I trial to study the effectiveness of interleukin-2 plus bryostatin 1 in treating patients who have melanoma or kidney cancer that cannot be removed during surgery.
Full Description
OBJECTIVES:
Determine the dose of bryostatin 1 that, when administered in conjunction with low-dose interleukin-2, maximizes in vitro interleukin-2- stimulated peripheral blood stem cell proliferation in patients with melanoma or renal cell carcinoma.
Assess other intermediate markers of immune response in patients treated with this regimen.
Determine tumor responses, response durations, progression-free intervals, and survival of patients treated with this regimen.
OUTLINE: This is a randomized, double-blind study. Patients are randomized to one of three bryostatin 1 dose levels.
Patients receive interleukin-2 subcutaneously daily on days 1-5 and bryostatin 1 IV over 1 hour on day 1 weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 21 patients will be accrued for this study within 2 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed cutaneous or mucosal melanoma or renal cell carcinoma
Unresectable disease
No known uncontrolled CNS metastases
CNS metastases allowed only if recently irradiated or known to be controlled
PATIENT CHARACTERISTICS:
Age:
18 and over
Performance status:
ECOG 0-1
Life expectancy:
Not specified
Hematopoietic:
Hemoglobin at least 8 g/dL
WBC at least 3,000/mm^3
Platelet count at least 100,000/mm^3
Absolute lymphocyte count at least 1,000/mm^3
Hepatic:
Total bilirubin no greater than 1.5 mg/dL OR
Conjugated bilirubin no greater than 0.3 mg/dL
AST no greater than 2.5 times upper limit of normal
Renal:
Creatinine no greater than 2 mg/dL
Cardiovascular:
No myocardial infarction within the past 6 months
No uncontrolled hypertension, angina, or congestive heart failure
Other:
Not pregnant or nursing
Fertile patients must use effective contraception during and for 3 months after study
No known intolerance to acetaminophen
No primary or secondary immunodeficiency
No other condition that would preclude study
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Not specified
Chemotherapy:
Not specified
Endocrine therapy:
At least 1 month since prior topical, systemic, or inhaled corticosteroids
No concurrent topical, systemic, or inhaled corticosteroids
Radiotherapy:
See Disease Characteristics
Surgery:
Not specified
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Lebanon New Hampshire, 03756, United States
Richmond Virginia, 23219, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.